GlobeNewswire by notified

Intertrust and CSC agree on recommended all-cash offer of EUR 20.00 per share



This is a joint press release by Intertrust N.V. ("Intertrust" or the "Company") and Corporation Service Company ("CSC" or the "Offeror") pursuant to the provisions of Section 4, paragraphs 1 and 3, Section 5, paragraph 1 and Section 7, paragraph 4 of the Netherlands Decree in Public Takeover Bids (Besluit openbare biedingen Wft, the "Decree") in connection with the intended recommended public offer (the "Offer") by the Offeror for all the issued and outstanding ordinary shares in the capital of Intertrust. This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities in Intertrust. Any offer will be made only by means of an offer memorandum (the "Offer Memorandum") approved by the AFM. This announcement is not for release, publication or distribution, in whole or in part, in or into, directly or indirectly, the United States, Canada and Japan.

Intertrust and CSC agree on recommended all-cash offer of EUR 20.00 per share

Wilmington, Delaware, USA / Amsterdam, the Netherlands – 6 December 2021 – Corporation Service Company ("CSC"), a leading provider of corporate, legal, tax, and digital brand services, and Intertrust N.V. ("Intertrust" or the "Company") [Euronext: INTER], a global leader in providing tech-enabled fund and corporate solutions, announce that a conditional agreement (the "Merger Agreement") has been reached on a recommended public offer (the "Offer") for all issued and outstanding ordinary shares of Intertrust (the "Shares") for EUR 20.00 (cum dividend) in cash per Share (the "Offer Price"). The Offer represents a total consideration of approximately EUR 1.8 billion.

Transaction highlights
•        CSC and Intertrust have reached conditional agreement on a recommended all-cash public offer for all issued and outstanding shares in the capital of Intertrust at an offer price of EUR 20.00 (cum dividend) per Share, representing a total consideration of approximately EUR 1.8 billion
•        The combination of CSC and Intertrust creates a differentiated leader for corporate, fund, private, and capital markets clients on an international scale, built on the combined strengths of each other’s global teams with complementary geographical and service offering strengths
•        The Offer Price represents a premium of approximately 59% to the undisturbed Intertrust closing share price on 11 November 2021, a premium of approximately 53% to the 30-day undisturbed VWAP and a premium of approximately 54% to the 90-day undisturbed VWAP, delivering immediate, certain and attractive value to Intertrust's shareholders
•        The Management Board and Supervisory Board of Intertrust (together, the "Intertrust Boards") fully and unanimously support the Offer and the transactions contemplated in connection therewith, including the post-closing restructuring, (together with the Offer, the "Transaction") and recommend the Offer to the shareholders of Intertrust
•        The Offeror has committed financing in place providing high deal certainty and will fund the transaction through a combination of debt and cash available resources
•        CSC and its subsidiaries (the "Offeror's Group") and Intertrust and its subsidiaries (the "Intertrust Group", and together the "Combined Group") will fully benefit from the reach, scale and resources of the combined businesses and CSC intends to invest in existing and new opportunities to further expand the business of the Combined Group and ensure the long-term interests of Intertrust's stakeholders, including its employees and clients
•        It is envisaged that the Offeror's and Intertrust's businesses will be aligned in order to fully benefit from CSC's strong culture, core values, and business model while respecting Intertrust's own particular culture and values based on a joint strategy that will further develop prior to settlement of the Offer ("Settlement")
•        CSC has agreed to Non-Financial Covenants (as defined below) for the first two (2) years following Settlement, which may only be deviated from with the consent from the Independent Supervisory Board Members (as defined below), including:
o     Intertrust Group's headquarters will remain in Amsterdam, the Netherlands
o     The Offeror will not divest or transfer any material part of the Intertrust Group
o     The Offeror will ensure that Intertrust remains prudently financed to support the success of the business and the Combined Group will maintain a financial leverage at a sustainable level to safeguard the Intertrust Group's sustainable continuity
•       Two Independent Supervisory Board Members (as defined below) will monitor and protect the interests of all Intertrust's stakeholders, including by monitoring compliance with non-financial  covenants 
•      The proposed transaction is subject to obtaining Regulatory and Competition Clearances and the Offeror has agreed to take the necessary steps to obtain such clearances

•       A first draft of the Offer Memorandum will be submitted to the AFM no later than in February 2022 with completion of the Offer anticipated in the second half of 2022

Hélène Vletter-Van Dort, Chairperson of the Supervisory Board of Intertrust: “The Supervisory Board unanimously recommends and supports the offer of CSC as we believe it is in the best interest of Intertrust and all its stakeholders. Our conclusions are that the offer price proposed by CSC represents compelling value at an attractive premium for shareholders. By combining the two companies, a truly global service provider will be created in the areas of corporate, fund, capital market, and private wealth services. In the past months, we received multiple expressions of interest from different parties to acquire Intertrust. We have engaged in discussions with all parties, ensuring a fair and thorough process. We have been evaluating a wide range of considerations and we are confident this outcome is in the interests of all stakeholders.”

Shankar Iyer, CEO of Intertrust: “We have thoroughly considered various options to drive value for our stakeholders. We believe this offer is in the interests of shareholders and provides a near term opportunity to crystallise value. In CSC we have found a long-term partner that is highly complementary to us, given its strong position in the United States and complementary service offerings. As a result, we will be able to offer a wider breath of services to our clients in even more geographical locations. The combination will enable us to strengthen our position as a leading tech-enabled Corporate and Fund Services provider and accelerate our transformation by expediting digitalisation initiatives. Moreover, founded in 1899, CSC has a strong reputation with similar cultural values and focus to Intertrust.”

Rodman Ward III, CEO of CSC: “We have been following Intertrust’s growth and transformation for many years, while at the same time building and growing our trust and corporate services offering in the United States, scaling our fund administration and international expansion solutions globally, and providing a service model to our clients to enable them to navigate an increasingly complex international regulatory environment. We are happy to submit an offer to Intertrust and feel we present a unique opportunity unmatched in the market due to our business model, our people, our industry-leading and award-winning customer service, stability, continuity, and our passion for the complex.

CSC believes that by combining its global corporate offering with Intertrust, it will establish itself as the differentiated leader for corporate, fund, private, and capital markets clients at a time that the market needs it most. By combining the strengths of the two businesses, CSC believes it will become the preferred partner to help companies manage their needs with a full suite of core and specialized services provided by industry experts and supported by a single-source technology platform.”


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Hoylu AB (publ) carries out a SEK 15 million convertible loan notes issue24.1.2022 23:30:00 CET | Press release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. The Board of Directors of Hoylu AB (publ) (“Hoylu” or the “Company”) has, with support of authorization granted by the annual general meeting on 21 May 2021, carried out a directed issue of convertible loan notes corresponding to a value of SEK 15 million. The convertible loan notes have been subscribed by Fougner Invest AS, Trellevika Invest AS, Fredrik Fougner, Alden AS, TTC Invest AS, Bimo Kapital AS, Helling Invest AS, Torsen Tankers & Towers AS, Camelback Holding AS, Camelback Eiendom AS, Nucleus Life AG, OneTwo3 AS, Norse Partners AS, Norse AS, Erling Johnsen A/S, Frenisa

PCI Biotech: Update on the RELEASE trial24.1.2022 21:00:00 CET | Press release

Oslo (Norway), 24 January 2022 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the company has decided to stop the RELEASE study and focus their drug development efforts on the promising immunotherapy opportunities with both fimaVacc and fimaNAc assets. The decision to stop the RELEASE study is based on recent randomised Phase III clinical trial results presented at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium (ASCO GI, January 20-22, 2022) from the TOPAZ-1 study, demonstrating that a combination of immune checkpoint inhibition with gemcitabine and cisplatin provides a significant survival benefit to patients with advanced biliary tract cancer compared with placebo plus gemcitabine and cisplatin. These results are expected to rapidly change the first line standard treatment for patients with unresectable perihilar or distal bile duct cancer, which is the intended patient population of the RELEASE trial. Such a c

Bombardier Announces New Sales Team Appointments24.1.2022 18:06:50 CET | Press release

MONTREAL, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Bombardier today announced strategic changes to its international sales leadership team. The changes, which take effect immediately, are designed to further optimize Bombardier’s worldwide sales experience and capitalize on robust demand for its market-leading, smooth-flying business jets. Following his decision to leave the company to pursue personal opportunities, Christophe Degoumois, Vice President, Sales, International has transitioned leadership to multiple Sales team members. An accomplished sales leader, Christophe leaves behind a solid foundation on which Bombardier has built its customer-centric values. “We are grateful for Christophe’s 17 years of dedicated service at Bombardier, as well as the team he has built, now ready to take on broader responsibilities,” said Peter Likoray, Senior Vice President, Sales, New Aircraft. “Christophe played an important role in creating a positive experience for our customers and instilling a sale

PRESS RELEASE: BIGBEN: RETURN TO GROWTH FOR Q3 2021/22 (+4,5%)24.1.2022 17:50:00 CET | Press release

Bigben Press release Lesquin, 24 January 2022 – 18:00 RETURN TO GROWTH FOR Q3 2021/22 (+4,5%) CONFIRMATION OF 2021/22& 2022/23 TARGETS IFRS – M€2021/22 2020/21 Change Sales1st Half-year (April - Sept.)124.2135.8-8.5%Nacon Gaming73.086.6-15.7%Bigben Audio / Telco51.249.2+4.1%3rdQuarter (Oct. - Déc.) (1)91.387.3+4.5%Nacon Gaming51.248.6+5.2%Bigben AudioVideo / Telco40.138.7+3.5%Cumulative 9 months (Apr.–Dec.) (1)215.4223.1-3.4%Nacon Gaming124.2135.3-8.2%Bigben AudioVideo / Telco91.287.8+3.9% (1) Non audited data Highlights: As expected, the 3rd quarter of FY 2021/22 returned to growth after a first half impacted by a high comparison basis. Driven by the sound performance of both business units, Group sales rose by 4.5% over the period to 91.3 M€. As a result, cumulative sales for the first nine months of FY 2021/22 reached 215.4 M€, representing a limited year-on-year decline of 3.4%, after an 8.5% fall in the first half. At the end of the 4th quarter, the Bigben Group should achieve the

Scandinavian Tobacco Group’s Board of Directors intends to elect Henrik Brandt as Chairman as Nigel Northridge has decided to retire at the next Annual General Meeting24.1.2022 17:48:27 CET | Press release

Company Announcement No. 6/2022 Copenhagen, 24 January 2022 Scandinavian Tobacco Group’s Board of Directors intends to elect Henrik Brandt as Chairman as Nigel Northridge has decided to retire at the next Annual General Meeting Nigel Northridge, Chairman of the Board of Directors of Scandinavian Tobacco Group A/S, has informed the Board of Directors that he will not stand for re-election at the Annual General Meeting on 31 March 2022. Nigel Northridge joined the Board of Directors in 2016 and has been Chairman of the Board of Directors since 2017. Subject to the elections at the Annual General Meeting in March 2022, the Board of Directors will elect Henrik Brandt as the new Chairman of the Board of Directors. Henrik Brandt joined the Board in 2017 as Vice-chairman. Vice-chairman Henrik Brandt says: “Nigel has been the Chairman during a period of significant change and growth for Scandinavian Tobacco Group. During his tenure, the Company has developed from being newly listed to a strong

PRESS RELEASE: NACON: RETURN TO GROWTH FOR Q3 2021-22 (+5,2%)24.1.2022 17:45:00 CET | Press release

NACON Press release Lesquin, 24 January 2022 – 18:00 RETURN TO GROWTH FOR Q3 2021-22 (+5,2%) CONFIRMATIONOF2021/22 & 2022/23TARGETS IFRS – M€2021/22 2020/21 Change Sales 1st Quarter (April-June) 33.738.0-11.3% 2nd Quarter (July-September) 39.348.6-19.1%3rd Quarter (Oct.-Dec.) (1)51.248.6+5.2%Games14.313.8+3.4%Accessories34.932.5+7.4%Others(2)2.02.3-14.4%Cumulative 9 months (April-Dec.) (1)124.2135.3-8.2%Games41.646.6-10.9%Accessories78.784.1-6.4%Others(2)4.04.5-12.2%(1)Non audited data(2)Mobile and Audio sales Q3 sales rebound to 51.2 M€ i.e. +5.2% In Q3 2021/22, Nacon returned to growth after two quarters which had been impacted by a very high comparison basis due to the lockdown periods favourable to the business. Sales growth over the period was driven by the strong performance of the games catalogue* and gaming accessories. GAMES The Video Games business posted sales of 14.3 M€, up 3.4% over the quarter. This increase was driven by the release of Cricket 22®, which got off to a com

Information on the outcome of the First Extraordinary General Meeting of Shareholders, and Convening Notice for a reconvened Extraordinary General Meeting of Shareholders24.1.2022 17:38:10 CET | Press release

Information on the outcome of the First Extraordinary General Meeting of Shareholders, and Convening Notice for a reconvened Extraordinary General Meeting of Shareholders MILLICOM INTERNATIONAL CELLULAR S.A. Registered Address: 2, Rue du Fort Bourbon L-1249 Luxembourg, Grand-Duchy of Luxembourg – R.C.S. Luxembourg: B40630 – I. OUTCOME OF THE FIRST EXTRAORDINARY MEETING OF SHAREHOLDERS The EGM was initially convened to be held on Monday, January 24, 2022, at 4:00pm CET (the “First EGM”). As the quorum required pursuant to article 450-3 of the law of 10 August 1915 on commercial companies, as amended, and article 21 of the Company’s articles of association was not met at the First EGM, the EGM is hereby reconvened in accordance with applicable law pursuant to the terms of this notice (see sections II-IX below). It is noted that at the First EGM, 44,564,846 shares of the Company were represented constituting approximately 44.48 per cent of the Company’s share capital excluding treasury sh